The obesity epidemic continues to run rampant in our country. In fact, a recent analysis published in The Lancet states that the rate of obesity has more than doubled for women and tripled for men. If this trend continues, it is expected that about one-fifth of adults will be obese by 2025.
NYU Winthrop is committed to the fight against obesity and the various medical conditions that can arise as a result, such as diabetes. Recently, the Hospital not only made headlines as one of the first sites in the country to offer vBloc Neurometabolic Therapy to patients, but for becoming the first employer in the United States to add it as a benefit for eligible employees and their spouses, at no charge!
“At NYU Winthrop, when we say ‘Your Health Means Everything,’ we truly believe it – not only for our patients but for our employees as well,” said John Collins, President and CEO of NYU Winthrop Hospital . “vBloc Neurometabolic Therapy aligns with our mission to provide high quality, safe and comprehensive healthcare, while also helping to address the significant healthcare costs associated with obesity.”
vBloc Neurometabolic Therapy, delivered via a small pacemaker device under the skin, is designed to intermittently block the nerves between the brain and stomach to produce earlier feelings of fullness and less hunger, resulting in a balanced, lower calorie diet and clinically meaningful weight loss. The system is implanted via outpatient surgery and does not restrict or alter the anatomy. Recovery time is minimal, and people can resume normal activity within a very short time. What’s more, individuals who undergo the therapy can achieve meaningful weight loss without restricting their food choices and lifestyle. They simply eat less because they feel full sooner.
In addition to losing weight, the health benefits of the therapy are proven. Eighty- five percent of vBloc patients in a feasibility study were able to maintain, decrease or even discontinue their diabetes medications while achieving improved glycemic control at 12 months. In fact, many patients who lost weight with vBloc experienced improved LDL cholesterol levels, lowered triglycerides, lowered blood pressure, lowered heart rate and reduced waist circumference.
“Obesity is the number one health crisis facing Americans today,” said Collin Brathwaite, MD, Chairman of Surgery and the Chief of the Division of Minimally Invasive Surgery and Director of the Bariatric Surgery Program at NYU Winthrop Hospital . “vBloc is a first-of-its-kind treatment option that fills a gap between behavior modification or pharmaceutical options and restrictive, anatomy altering surgical options, offering safe, durable weight loss without compromising anatomy or daily lifestyle. With more choices and greater innovation, NYU Winthrop’s goal is to turn the tide in the fight against obesity.”
For additional information about vBloc Neurometabolic Therapy or other weight loss programs and procedures at NYU Winthrop, please call1-866-WINTHROP or visit www.winthrop.org.